RadiotherapyFDA-approvedSecond-line
Lutetium-177 vipivotide tetraxetan
How it works
Delivers targeted radiation to prostate cancer cells, killing them through ionizing radiation.
Cancer types
Efficacy
Studies show that lutetium-177 vipivotide tetraxetan can improve overall survival and reduce symptoms in patients with advanced prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.